Press Releases May 14, 2026 12:13 PM

CTS Corporation Declares a Dividend

CTS Corporation declares quarterly cash dividend to reward shareholders

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
CTS

CTS Corporation's Board of Directors has declared a cash dividend of $0.04 per share, payable on July 24, 2026, to shareholders of record as of June 26, 2026. CTS is a US-based designer and manufacturer of sensors, actuators, and electronic components serving aerospace, defense, industrial, medical, and transportation sectors.

CTS Corporation Declares a Dividend
CTS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CTS declared a quarterly cash dividend of $0.04 per share.
  • Dividend payable on July 24, 2026, to shareholders of record June 26, 2026.
  • CTS operates globally manufacturing sensors and electronic components for aerospace, defense, medical, industrial, and transportation sectors.

LISLE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE: CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on July 24, 2026, to shareholders of record at the close of business on June 26, 2026.

About CTS

CTS Corporation (NYSE: CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical and transportation markets. For more information, visit www.ctscorp.com.

Contact

Ashish Agrawal
Vice President and Chief Financial Officer
CTS Corporation
4925 Indiana Avenue
Lisle, IL 60532 USA
+1 (630) 577-8800
ashish.agrawal@ctscorp.com


Risks

  • Dividend declaration does not guarantee future dividend payments and depends on company performance and market conditions.
  • Global supply chain disruptions may impact CTS's manufacturing capabilities.
  • Economic downturns in aerospace, defense, and transportation markets could reduce demand for CTS products.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026